AR and Familial prostate cancer: Increasing evidence suggests that expression of AR variants is upregulated during castration-resistant progression of prostate cancer and that increased expression of AR variants may contribute to resistance to antiandrogen therapies (Hörnberg et al., 2011; Hu et al., 2012; Li et al., 2013; Sun et al., 2010; Watson et al., 2010).